Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trialsScheeren, T. W. L., Welte, T., Saulay, M., Engelhardt, M., Santerre-Henriksen, A. & Hamed, K., 26-Feb-2019, In : BMC Infectious Diseases. 19, 12 p., 195.
Research output: Contribution to journal › Article › Academic › peer-review
BackgroundPatients with pneumonia who are elderly or severely ill are at a particularly high risk of mortality. This post hoc retrospective analysis of data from two Phase III studies evaluated early improvement outcomes in subgroups of high-risk patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia [VAP]).MethodsOne study included hospitalised CAP patients randomised to ceftobiprole or ceftriaxone linezolid treatment. The other study included HAP patients, who were randomised to ceftobiprole or ceftazidime plus linezolid treatment. The primary outcome was rate of early clinical response (Day 3 in CAP and Day 4 in HAP patients). Additional outcome measures included clinical cure at a test-of-cure visit, 30-day all-cause mortality and safety.ResultsThe overall high-risk group comprised 398 CAP patients and 307 HAP patients with risk factors present at baseline. The rate of early response was numerically higher in ceftobiprole-treated patients vs comparator-treated patients in the following high-risk groups: CAP patients aged 75years (16.3% difference, 95% confidence interval [CI]: 1.8, 30.8); CAP patients with COPD (20.1% difference, 95% CI: 8.8, 31.1); all high-risk HAP patients (12.5% difference, 95% CI: 3.5, 21.4); HAP patients with >10 baseline comorbidities (15.3% difference, 95% CI: 0.3, 30.4).ConclusionsPrevious studies show that ceftobiprole is an efficacious therapy for patients with pneumonia who are at high risk of poor outcomes. This post hoc analysis provides preliminary evidence that ceftobiprole treatment may have advantages over other antibiotics in terms of achieving early improvement in high-risk patients with HAP (excluding VAP) and in some subgroups of high-risk CAP patients.Trial registration NCT00210964: registered September 21, 2005; NCT00229008: registered September 29, 2005; NCT00326287: registered May 16, 2006.
|Number of pages||12|
|Journal||BMC Infectious Diseases|
|Publication status||Published - 26-Feb-2019|
- Ceftobiprole, Cephalosporin, Community-acquired pneumonia, Hospital-acquired pneumonia, COMMUNITY-ACQUIRED PNEUMONIA, REGISTRATIONAL CLINICAL-TRIALS, BIOMARKERS CONSORTIUM, PROGNOSTIC-FACTORS, ECONOMIC BURDEN, END-POINTS, MEDOCARIL, ADULTS, MORTALITY, HOSPITALIZATIONS